TCRT on Nasdaq

ZIOPHARM Oncology

Publicly held, clinical-stage biopharmaceutical company.1

Price unavailable

Last updated Oct 19, 2026.

Overview

Jan 1, 2005Founded1

Compare with Processa Pharmaceuticals, Inc., One World Products, Inc. or Aspire-Lakewood Holdings, Inc., or pick any stock.

  • TickerTCRT on Nasdaq1
  • Industrypharmaceutical industry1
  • HeadquartersBoston1
  • Websitewww.ziopharm.com
  • Incorporated inDE3
  • Business address501 E Las Olas Blvd, Suite 300, Fort Lauderdale, Fl 333013
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

We are a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. On March 2, 2026, we announced positive preclinical proof-of-concept data for ALN1003 from two separate studies using a standard diet-induced obesity (DIO) mouse model in male C57BL/6 mice maintained on a high-fat diet (60% of calories from fat). Highlights from these studies include dose-dependent body weight loss with favorable body composition changes, reductions in liver weight, improvement in liver function biomarkers, and improvement in metabolic biomarkers. Collective…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-84500.0%Operating margin5
-83520.0%Net margin5
-50.0%Revenue growth, 20255
-194.0%Return on equity5
-$3.0MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$1.4M

Out of $5.0K in revenue.5 The company lost money this year.

Financial statements

Revenue67895$5.0K in 2025
0$1.0M$2.0M$3.0M2020: $0$020202021: $398.0K$398.0K20212022: $2.9M$2.9M2022+634%2023: $5.0K$5.0K2023−100%2024: $10.0K$10.0K2024+100%2025: $5.0K$5.0K2025−50%
Operating income1067895-$4.2M in 2025−93% since 2019
-$100.0M-$75.0M-$50.0M-$25.0M02019: -$57.9M-$57.9M20192020: -$80.4M-$80.4M2020+39%2021: -$77.5M-$77.5M2021−3%2022: -$35.1M-$35.1M2022−55%2023: -$34.3M-$34.3M2023−2%2024: -$4.8M-$4.8M2024−86%2025: -$4.2M-$4.2M2025−12%
Net income106785-$4.2M in 2025−96% since 2019
-$150.0M-$100.0M-$50.0M02019: -$117.8M-$117.8M20192020: -$80.0M-$80.0M2020−32%2021: -$78.8M-$78.8M2021−2%2022: -$37.7M-$37.7M2022−52%2023: -$4.7M-$4.7M2023−88%2024: -$4.7M-$4.7M2024+0%2025: -$4.2M-$4.2M2025−11%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Revenue$5.0K$10.0K
Research and development$1.4M$362.0K
General and administrative$2.9M$4.5M
Total operating expenses$4.2M$4.8M
Loss from operations-$4.2M-$4.8M
Change in fair value of warrant liability-$31.0K$0
Other income , net$80.0K$133.0K
Other income (expense), net$49.0K$133.0K
Net loss-$4.2M-$4.7M-$4.7M
Earnings per share, Basic-$2.20-$2.92
Earnings per share, Diluted-$2.20-$2.92
Weighted average common shares outstanding, basic1.9M shares1.6M shares
Weighted average common shares outstanding, diluted1.9M shares1.6M shares

Compare ZIOPHARM Oncology with another company

Leadership

Who has led ZIOPHARM Oncology, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Laurence James Neil Cooper2015–2021
  2. Heidi Hagen2021
  3. Kevin S. Boyle Sr.2021–2023
  4. Dale Curtis Hogue Jr.2024
  5. Holger Weis2025–now

President

  1. Richard E. Bagley2006–2012
  2. Hagop Youssoufian2013
  3. David M. Mauney Md.2019–2020
  4. Laurence James Neil Cooper2021

Chief financial officer

  1. Jason Amello2012–2013
  2. Sath Shukla2019–2020
  3. Timothy M. Cunningham2021

Chief operating officer

  1. Richard E. Bagley2006–2012
  2. Caesar J. Belbel2015–2018
2010201520202025
Board members and other officers (39)

Former names

  • ZIOPHARM ONCOLOGY INCSep 20, 2005 to Jan 4, 20223
  • EASYWEB INCFeb 13, 2001 to Sep 19, 20053

Timeline

  1. Jul 7, 2025New chief executive Holger Weis becomes CEO13
  2. Jan 23, 2024New chief executive Dale Curtis Hogue Jr. becomes CEO14
  3. Aug 31, 2021New chief executive Kevin S. Boyle Sr. becomes CEO16
  4. Mar 8, 2021New chief executive Heidi Hagen becomes CEO15
  5. May 7, 2015New chief executive Laurence James Neil Cooper becomes CEO17
  6. Nov 9, 2005Went public Listed on NASDAQ1
  7. Jan 1, 2005Founded Founded1

Filings

251 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 75 major events, 89 insider forms, 27 large holders, 38 other. The latest 20:

  1. Oct 15, 20263 EDGAR
  2. Oct 15, 2026SCHEDULE 13D EDGAR
  3. Oct 15, 2026SCHEDULE 13D/A EDGAR
  4. Oct 13, 20268-K EDGAR
  5. Oct 9, 20268-K EDGAR
  6. Oct 8, 20264 EDGAR
  7. Oct 8, 20264 EDGAR
  8. Oct 8, 20264 EDGAR
  9. Oct 8, 20264 EDGAR
  10. Sep 22, 20268-K EDGAR
  11. Sep 21, 2026424B3 EDGAR
  12. Sep 17, 20268-K EDGAR
  13. Aug 14, 202610-Q EDGAR
  14. Aug 11, 20264 EDGAR
  15. Jul 27, 20264 EDGAR
  16. Jul 27, 20264 EDGAR
  17. Jul 27, 20264 EDGAR
  18. Jul 27, 20264 EDGAR
  19. Jul 6, 2026S-8 EDGAR
  20. Jul 2, 20264 EDGAR

The 251 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 4 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 31, 2024Vieser JaimeDirectorSale3,000$2.01$6.0KForm 4
Sep 1, 2023Boyle Kevin S. Sr.Chief Executive OfficerSale68,014$0.14$9.5KForm 4
Nov 29, 2022Postma Robert WDirectorBuy750,000$0.65$487.5KForm 4
Nov 29, 2022Vieser JaimeDirectorBuy1,250,000$0.65$812.5KForm 4
Dec 22, 2021De Groot EleanorEVP, OperationsSale20,132$1.27$25.6KForm 4
Nov 17, 2021Boyle Kevin S. Sr.Chief Executive OfficerBuy9,116$1.40$12.8KForm 4
Nov 16, 2021Boyle Kevin S. Sr.Chief Executive OfficerBuy884$1.40$1.2KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 29. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.21,353$48.3K0.0%No change
Geode Capital Management, LLC19,356$43.8K0.0%−3,204
Vanguard Fiduciary Trust Co15,497$35.0K0.0%No change
Vanguard Capital Management LLC14,063$31.8K0.0%No change
Citadel Advisors LLC11,870$26.8K0.0%+1,351
Osaic Holdings, Inc.1,731$3.9K0.0%−48
Tower Research Capital LLC (TRC)1,621$3.7K0.0%+38
Arax Advisory Partners1,216$2.7K0.0%New
UBS Group AG992$2.2K0.0%−1,282
Morgan Stanley836$1.9K0.0%+183
Vanguard Global Advisers, LLC501$1.1K0.0%No change
Royal Bank Of Canada375$1.0K0.0%+190
Wells Fargo & Company/mn388$8770.0%+198
Blue Trust, Inc.135$3050.0%No change
Steward Partners Investment Advisory, LLC112$2530.0%+20
Federation des caisses Desjardins du Quebec70$1580.0%No change
Bokf, Na66$1490.0%New
Axiom Investment Management LLC46$1040.0%New
Key Financial Inc24$540.0%No change
Signaturefd, LLC23$520.0%No change
NFSG Corp21$470.0%No change
Lanark Financial, Inc.20$450.0%No change
AdvisorNet Financial, Inc19$430.0%No change
Barclays PLC15$340.0%New
West Paces Advisors Inc.10$230.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73